Plasma Fractionation Market Overview
Cohn and colleagues invented plasma fractionation, the first large-scale protein purification method, nearly 60 years ago. Human serum albumin (HSA), immunoglobulin (IG), coagulation factor VIII, and protease inhibitors are currently therapeutically significant proteins. The global Plasma Fractionation market is expected to grow at a significant rate in the coming years.
The global plasma fractionation market is expected to be propelled by an increase in demand for plasma proteins, increased investment in innovation, and an increase in the occurrence of uncommon diseases around the world. The plasma fractionation industry has been investing in the research and development of new plasma protein therapies, which have resulted in innovative medicines for patients' benefit. Furthermore, increased investment in research and development leads to technological advances in efficient and cost-effective processes for fractionating proteins from plasma, boosting the plasma fractionation market.
On the negative side, increasing market penetration by recombinant factors and strict regulations and reimbursement problems are key factors limiting the growth of the global plasma fractionation market.
| Report Metric | Details |
| Market size available for years | 2023–2030 |
| Base year considered | 2023 |
| Forecast period | 2024–2030 |
| Forecast unit | Value (USD Million) |
| Segments covered | Product Type, Applications, End use, and Region |
| Regions covered | North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA) |
| Companies covered | CSL Limited, Shire plc, Sanquin, Biotest AG., GRIFOLS, Baxter International Inc., Kedrion, Octapharma and China Biologic Products Holdings, Inc. |
Covid-19 Impact on Plasma Fractionation Market
In addition, the current Plasma Fractionation Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Plasma Fractionation Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Plasma Fractionation Market Segment Overview
Based on Product Type, the Immunoglobulin segment dominates the global plasma fractionation market. This is due to the increased occurrence of autoimmune diseases such as primary humoral immunodeficiency (PIDD), multiple sclerosis, immune thrombocytopenia purpura (ITP), autoimmune hemolytic anemia, and Kawasaki syndrome. This aspect increases the rate of adoption of immunoglobulins, which in turn boosts the market. Moreover, according to application, neurology is another important segment in the global plasma fractionation market. An increase in the number of neurological disorders enhances the growth of the segment.
Plasma Fractionation Market, By Product Type
- Immunoglobulin
- Intravenous Immunoglobulin
- Subcutaneous Immunoglobulin
- Coagulation Factor Concentrates
- Factor VIII
- Factor IX
- Factor XIII
- Prothrombin Complex Concentrate
- Von Willebrand Factor
- Fibrinogen Concentrates
- Albumin
- Protease Inhibitors
- Other
Plasma Fractionation Market, By Application
· Neurology
· Immunology
· Hematology
· Critical Care
· Pulmonology
· Other
Plasma Fractionation Market, By End User
· Hospitals and Clinics
· Clinical Research Laboratories
· Academic Institutes
Plasma Fractionation Regional Overview
Region-Wise, North America, and Europe are two major regions for the global Plasma Fractionation market. The high occurrence of infectious diseases such as cholera, influenza, and syphilis in North America propelled the demand for the utilization of plasma fractionation. Likewise, Europe accounted for a prominent share of the market. This is because of the presence of a large old age population that is more prone to infections. Similarly, because of the large patient population, inadequate sanitization, and low awareness of plasma fractionation products among the people in the region, Asia Pacific is considered a developing market for plasma fractionation.
Plasma Fractionation Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Plasma Fractionation Market, Key Players
· CSL Limited
· Shire plc
· Sanquin
· Biotest AG.
· GRIFOLS
· Baxter International Inc.
· Kedrion
· Octapharma and China Biologic Products Holdings, Inc.
Frequently Asked Questions (FAQ) :
Q1. What are the driving factors for the Plasma Fractionation market?
The global plasma fractionation market is expected to be propelled by an increase in demand for plasma proteins, increased investment in innovation, and an increase in the occurrence of uncommon diseases around the world
Q2. What are the restraining factors for the Plasma Fractionation market?
Increasing market penetration by recombinant factors and strict regulations and reimbursement problems are key factors limiting the growth of the global plasma fractionation market
Q3. Which segment is projected to hold the largest share in the Plasma Fractionation Market?
The immunoglobulin segment is projected to hold the largest share in the Plasma Fractionation Market.
Q4. Which region holds the largest share in the Plasma Fractionation market?
North America held the largest share in the global Plasma Fractionation market
Q5. Which are the prominent players in the Plasma Fractionation Market?
CSL Limited, Shire plc, Sanquin, Biotest AG., GRIFOLS, Baxter International Inc., Kedrion, Octapharma and China Biologic Products Holdings, Inc. are some key players in the Plasma Fractionation Market.
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Plasma Fractionation Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Product Type
- 5.2.1. Immunoglobulin
- 5.2.1.1. Intravenous Immunoglobulin
- 5.2.1.2. Subcutaneous Immunoglobulin
- 5.2.2. Coagulation Factor Concentrates
- 5.2.2.1. Factor VIII
- 5.2.2.2. Factor IX
- 5.2.2.3. Factor XIII
- 5.2.2.4. Prothrombin Complex Concentrate
- 5.2.2.5. Von Willebrand Factor
- 5.2.2.6. Fibrinogen Concentrates
- 5.2.3. Albumin
- 5.2.4. Protease Inhibitors
- 5.2.5. Other
- 5.2.1. Immunoglobulin
- 5.3. Market Analysis, Insights and Forecast – By Application
- 5.3.1. Neurology
- 5.3.2. Immunology
- 5.3.3. Hematology
- 5.3.4. Critical Care
- 5.3.5. Pulmonology
- 5.3.6. Other
- 5.4. Market Analysis, Insights and Forecast – By End User
- 5.4.1. Hospitals and Clinics
- 5.4.2. Clinical Research Laboratories
- 5.4.3. Academic Institutes
- 5.5. Market Analysis, Insights and Forecast – By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America, Middle East and Africa
6. North America Plasma Fractionation Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Product Type
- 6.2.1. Immunoglobulin
- 6.2.1.1. Intravenous Immunoglobulin
- 6.2.1.2. Subcutaneous Immunoglobulin
- 6.2.2. Coagulation Factor Concentrates
- 6.2.2.1. Factor VIII
- 6.2.2.2. Factor IX
- 6.2.2.3. Factor XIII
- 6.2.2.4. Prothrombin Complex Concentrate
- 6.2.2.5. Von Willebrand Factor
- 6.2.2.6. Fibrinogen Concentrates
- 6.2.3. Albumin
- 6.2.4. Protease Inhibitors
- 6.2.5. Other
- 6.2.1. Immunoglobulin
- 6.3. Market Analysis, Insights and Forecast – By Application
- 6.3.1. Neurology
- 6.3.2. Immunology
- 6.3.3. Hematology
- 6.3.4. Critical Care
- 6.3.5. Pulmonology
- 6.3.6. Other
- 6.4. Market Analysis, Insights and Forecast – By End User
- 6.4.1. Hospitals and Clinics
- 6.4.2. Clinical Research Laboratories
- 6.4.3. Academic Institutes
- 6.5. Market Analysis, Insights and Forecast – By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Plasma Fractionation Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Product Type
- 7.2.1. Immunoglobulin
- 7.2.1.1. Intravenous Immunoglobulin
- 7.2.1.2. Subcutaneous Immunoglobulin
- 7.2.2. Coagulation Factor Concentrates
- 7.2.2.1. Factor VIII
- 7.2.2.2. Factor IX
- 7.2.2.3. Factor XIII
- 7.2.2.4. Prothrombin Complex Concentrate
- 7.2.2.5. Von Willebrand Factor
- 7.2.2.6. Fibrinogen Concentrates
- 7.2.3. Albumin
- 7.2.4. Protease Inhibitors
- 7.2.5. Other
- 7.2.1. Immunoglobulin
- 7.3. Market Analysis, Insights and Forecast – By Application
- 7.3.1. Neurology
- 7.3.2. Immunology
- 7.3.3. Hematology
- 7.3.4. Critical Care
- 7.3.5. Pulmonology
- 7.3.6. Other
- 7.4. Market Analysis, Insights and Forecast – By End User
- 7.4.1. Hospitals and Clinics
- 7.4.2. Clinical Research Laboratories
- 7.4.3. Academic Institutes
- 7.5. Market Analysis, Insights and Forecast – By Country
- 7.5.1. UK
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Italy
- 7.5.5. Spain
- 7.5.6. Russia
- 7.5.7. Rest of Europe
8. Asia Pacific Plasma Fractionation Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Product Type
- 8.2.1. Immunoglobulin
- 8.2.1.1. Intravenous Immunoglobulin
- 8.2.1.2. Subcutaneous Immunoglobulin
- 8.2.2. Coagulation Factor Concentrates
- 8.2.2.1. Factor VIII
- 8.2.2.2. Factor IX
- 8.2.2.3. Factor XIII
- 8.2.2.4. Prothrombin Complex Concentrate
- 8.2.2.5. Von Willebrand Factor
- 8.2.2.6. Fibrinogen Concentrates
- 8.2.3. Albumin
- 8.2.4. Protease Inhibitors
- 8.2.5. Other
- 8.2.1. Immunoglobulin
- 8.3. Market Analysis, Insights and Forecast – By Application
- 8.3.1. Neurology
- 8.3.2. Immunology
- 8.3.3. Hematology
- 8.3.4. Critical Care
- 8.3.5. Pulmonology
- 8.3.6. Other
- 8.4. Market Analysis, Insights and Forecast – By End User
- 8.4.1. Hospitals and Clinics
- 8.4.2. Clinical Research Laboratories
- 8.4.3. Academic Institutes
- 8.5. Market Analysis, Insights and Forecast – By Country
- 8.5.1. China
- 8.5.2. India
- 8.5.3. Japan
- 8.5.4. Australia
- 8.5.5. South East Asia
- 8.5.6. Rest of Asia Pacific
9. Latin America, Middle East and Africa Plasma Fractionation Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Product Type
- 9.2.1. Immunoglobulin
- 9.2.1.1. Intravenous Immunoglobulin
- 9.2.1.2. Subcutaneous Immunoglobulin
- 9.2.2. Coagulation Factor Concentrates
- 9.2.2.1. Factor VIII
- 9.2.2.2. Factor IX
- 9.2.2.3. Factor XIII
- 9.2.2.4. Prothrombin Complex Concentrate
- 9.2.2.5. Von Willebrand Factor
- 9.2.2.6. Fibrinogen Concentrates
- 9.2.3. Albumin
- 9.2.4. Protease Inhibitors
- 9.2.5. Other
- 9.2.1. Immunoglobulin
- 9.3. Market Analysis, Insights and Forecast – By Application
- 9.3.1. Neurology
- 9.3.2. Immunology
- 9.3.3. Hematology
- 9.3.4. Critical Care
- 9.3.5. Pulmonology
- 9.3.6. Other
- 9.4. Market Analysis, Insights and Forecast – By End User
- 9.4.1. Hospitals and Clinics
- 9.4.2. Clinical Research Laboratories
- 9.4.3. Academic Institutes
- 9.5. Market Analysis, Insights and Forecast – By Country
- 9.5.1. Brazil
- 9.5.2. Saudi Arabia
- 9.5.3. UAE
- 9.5.4. Rest of LAMEA
10. Competitive Analysis
- 10.1. Company Market Share Analysis, 2018
- 10.2. Key Industry Developments
- 10.3. Company Profile
- 10.4. CSL Limited
- 10.4.1. Business Overview
- 10.4.2. Segment 1 & Service Offering
- 10.4.3. Overall Revenue
- 10.4.4. Geographic Presence
- 10.4.5. Recent Development
- 10.5. Shire plc
- 10.6. Sanquin
- 10.7. Biotest AG.
- 10.8. GRIFOLS
- 10.9. Baxter International Inc.
- 10.10. Kedrion
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
